Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Five-year research partnership targets breast cancer vaccine

21 March 2017

Five-year research partnership targets breast cancer vaccine


A vaccine for breast cancer is on the horizon, thanks to a new partnership between Victoria University of Wellington’s Ferrier Research Institute and the Breast Cancer Foundation New Zealand (BCFNZ).

The five-year research partnership will see BCFNZ give the Ferrier Institute $500,000 to progress a significant breakthrough made by chemists at the Institute to create a life-saving breast cancer vaccine.

Ferrier Research Institute chemists are making gains in the area of cancer immunotherapy—described by leading journal Science as the ‘Breakthrough of the Year’ in 2013.

The Institute is developing a synthetic cancer vaccine technology that can activate tumour-specific T cells, producing a targeted immune response. This synthetic cancer vaccine causes rejection of cancer in several types of animal models.

Ferrier Institute director Professor Richard Furneaux says the technology is almost there. “We just need to get it to the next level of testing—human clinical trials.”

Professor Gavin Painter, who leads the chemistry team at Ferrier, says the support of BCFNZ is crucial.

“Getting a new therapy to human clinical trials requires significant investment, and an intensive campaign of chemistry, biology and regulatory compliance.

“Our success to date has been made possible because we work with the exceptional immunology research group led by Professor Ian Hermans at the Malaghan Institute of Medical Research here in Wellington, a relationship built up in a seven-year strategic collaboration.”

Evangelia Henderson, chief executive at BCFNZ says: “We went looking for a research partner who would give us the best shot of moving toward our vision of zero deaths from breast cancer. We were blown away by the calibre of the Ferrier team, the work they’d already done in the exciting field of immunotherapy and vaccines, and the strength of their international partnerships. It was a no-brainer for us.”

Cancer immunotherapy has caused a paradigm shift in cancer treatment, with a focus on targeting the body’s own immune system to fight cancer cells rather than introducing toxic agents to attack tumours directly. This line of research has led to the production of cancer vaccines which are showing promising results when used in certain situations; they are well tolerated by the body, have fewer side effects than current chemotherapy treatments and may be more effective in the long-term.

The successful immunotherapy treatment platform pioneered at Ferrier in collaboration with the Malaghan Insitute of Medical Research, has led to the establishment of biotechnology company Avalia Immunotherapies, which aims to commercialise the vaccine technology to help patients. Avalia’s chief executive officer is Victoria alumna Dr Shivali Gulab, a former NZBIO Young Bioscientist of the Year who is based in New York driving the progress of the vaccine technology towards human clinical trials.

For 20 years the Ferrier Research Institute has had an extensive working relationship with the Albert Einstein College of Medicine in New York which has resulted in successful drug trials. These include some of the most powerful enzyme inhibitors ever reported including Forodesine as a targeted therapy for a variety of haematological cancers, and Ulodesine as an orally available drug to treat severe gout.

View video: https://youtu.be/SlndAVxxfqQ


ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Our Fresh Water: Monitoring Report Confirms Serious Challenges For Rivers

• nitrogen levels are getting worse at 55 percent and getting better at 28 percent of monitored river sites across New Zealand • phosphorus levels are getting better at 42 percent and getting worse at 25 percent of monitored river sites across New Zealand More>>

ALSO:

Stats: Wind And Geothermal Emerge As Significant Sources Of Energy

Geothermal’s contribution to New Zealand’s total renewable energy generation increased from 11.5 percent in 2007 to 21 percent in 2015.... The value of wind jumped from $238 million (2 percent of total renewable energy generation) in 2007 to $884 million (6 percent) in 2015. More>>

Errors Found: Electricity Authority Dumps Transmission Pricing Modelling

The Electricity Authority is ditching the cost-benefit analysis at the heart of its controversial attempt to find a new way to divide up costs for the national grid after finding an expanding range of serious computational errors in the work by Australian consultancy Oakley Greenwood. More>>

ALSO:

New Record: Migrant Arrivals At 129,500 A Year

Annual net migration has been steadily increasing since 2012. "This was mainly due to the rising number of migrant arrivals to New Zealand," population statistics senior manager Peter Dolan said. "Fewer migrant departures also contributed to the increase in net migration." More>>

ALSO:

Launched: NASA's Super Pressure Balloon Takes Flight From NZ

NASA successfully launched its football-stadium-sized, heavy-lift super pressure balloon (SPB) from Wanaka, New Zealand, at10:50 a.m. Tuesday, April 25 (6:50 p.m. April 24 in U.S. Eastern Time), on a mission designed to run 100 or more days floating at 110,000 feet (33.5 km) about the globe in the southern hemisphere's mid-latitude band. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news